Turkish Validity and Reliability Study of The Bipolar Recovery Questionnaire

December 24, 2022 updated by: Zehra GÜNAY YAĞCI, Bilecik Seyh Edebali Universitesi
In addition to objective criteria (no episode period for 6 months) for defining and monitoring recovery, evaluation of subjective criteria is also very important. Various Turkish scales related to recovery in progressive diseases have been developed or validity-reliability studies have been conducted. However, as far as we know, there is no scale that evaluates subjective improvement for a disorder such as bipolar disorder that progresses in episodes and has a heterogeneous appearance of loss of functionality. In this study, we aimed to conduct a validity and reliability study of the recovery questionnaire for BDD.

Study Overview

Status

Active, not recruiting

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bilecik, Turkey, 11000
        • Bilecik Seyh Edebali University Faculty of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Bipolar Affective Disorder

Description

Inclusion Criteria:

  • Being between 18-65 ages
  • Be diagnosed with bipolar affective disorder
  • Be at least primary school graduate

Exclusion Criteria:

  • having a physical disability (blindness, etc.) that might prevent filling in the scales,
  • having an additional neurological disease that prevented filling out the scale items.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
validity and reability of scale
Time Frame: 5 months
turkish validity and reability of Bipolar Recovery Questionnare
5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 13, 2022

Primary Completion (Anticipated)

April 13, 2023

Study Completion (Anticipated)

May 13, 2023

Study Registration Dates

First Submitted

December 24, 2022

First Submitted That Met QC Criteria

December 24, 2022

First Posted (Estimate)

January 11, 2023

Study Record Updates

Last Update Posted (Estimate)

January 11, 2023

Last Update Submitted That Met QC Criteria

December 24, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • BilecikSeyhEU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bipolar Disorder, Recovery

Clinical Trials on validity and realibility of scale

3
Subscribe